JB Pharma stock reports 6.4 percent FY26 revenue growth

Published on 09/28/2026 at 10:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

JB Pharma stock stood at INR 2,416.10 on NSE on July 16, 2026, with a 0.30 percent daily gain. FY26 net profit reached INR 7.09 billion, up 7.6 percent.

JB Pharma, INE572A01036, Illustration mit AI erstellt.

JB Pharma stock, representing J. B. Chemicals & Pharmaceuticals Limited (ISIN INE572A01036), was last quoted at INR 2,416.10 on NSE on July 16, 2026, with a 0.30 percent daily gain. The company entered the new fiscal year after FY26 revenue rose 6.4 percent and net profit increased 7.6 percent.

FY26 revenue reached INR 42.08 billion

Univest reported FY26 revenue of INR 4,207.94 crore, equal to INR 42.08 billion, compared with growth of 6.4 percent year on year. FY26 net profit reached INR 709.47 crore, or INR 7.09 billion, up 7.6 percent from the prior year.

The same report identified Q4 FY26 revenue of INR 916.21 crore and net profit of INR 101.37 crore. Those figures place the March 2026 quarter at the center of the companys latest verified operating picture.

Analyst targets trail the quoted price

MarketScreener listed a BUY mean consensus from 8 analysts, with an average target price of INR 2,328.14, a high target of INR 2,744.00 and a low target of INR 1,900.00. The spread of targets shows that the consensus contains a wider valuation range than the headline average suggests.

JB Pharma operates across branded formulations, active pharmaceutical ingredients and contract development and manufacturing. Its portfolio includes gastroenterology, hypertension and dermatology products, while its international presence extends across Russia, South Africa, the United States, Asia, Africa and Latin America.

Stock remains near its yearly high

The July 16 reference price stood between the 52-week low of INR 1,638.50 and high of INR 2,525.50. At INR 2,416.10, the stock was 4.34 percent below that high, while the market capitalization was INR 387.9 billion and trading volume reached 4,779,224 shares on the same snapshot.

For investors, the central balance is clear: FY26 delivered quantified revenue and profit growth, while the average analyst target listed by MarketScreener remained below its quoted reference price. Future quarterly execution will determine whether the company can extend that earnings trajectory.